CliniMACS® CD56 Product Line

CD56 Product Line

CD56 is an isoform of the neural cell adhesion molecule (NCAM). Among human hematopoietic cell populations it is expressed on natural killer (NK) cells, natural killer T (NKT) cells, and on subpopulations of T cells, monocytes, and dendritic cells.
The CliniMACS
CD56 Product Line consists of murine anti-CD56 monoclonal antibodies conjugated to superparamagnetic iron dextran particles.
One vial contains 7.5 mL sterile, non-pyrogenic solution.
The performance of the CliniMACS CD56 Product Line depends on the individual separation strategy. For information on respective capacities, refer to the CliniMACS User Manual or contact your local representative.
Please inquire about required CliniMACS System components and accessories.


The CliniMACS
System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.
In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for in vitro use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations - e.g., for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") - must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.
In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved; all other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE).
CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research only and not for therapeutic or diagnostic use.


The CliniMACS CD56 Product Line was developed for the enrichment of NK and NKT cells from human heterogeneous hematologic cell populations in combination with the CliniMACS® System.
In order to enrich CD56
NK cells, the CliniMACS CD56 Reagent is used in combination with the CliniMACS CD3 Reagent. In this approach, the cellular product is first depleted of CD3
cells and subsequently enriched for CD56.

Referenced literature

NK cells and NKT cells may be a perfect tool to exert GvT effects in the transplant as well as in the non-transplant setting, since they have not been observed to induce GvHD. NK cell donor lymphocyte infusions (DLIs) have been infused in non-transplant and in haploidentical and unrelated donor PBSC transplantation settings in order to explore GvT effects.
Furthermore, the capacity to reduce risk for GvHD and early relapse of hematological malignant diseases (e.g. AML, CML) and the potential to emend an unstable donor chimerism after stem cell transplantation (SCT) are under clinical investigation.
  • Selected References

    1. Duwendag et al. (2004) 20th Int. NK Cell Workshop, Noordwijkerhout, NL.
    2. Iyengar et al. (2003) Purification of human natural killer cells using a clinical-scale immunomagnetic method. Cytotherapy 5(6): 479-484
    3. Leung, W. et al. (2004) Determinants of antileukemia effects of allogeneic NK cells. J. Immunol. 172: 644-650
    4. Giebel et al. (2003) Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102: 814-819
    5. Ruggeri, L. et al. (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295: 2097-2100
    6. Curti et al. (2007) Blood 110: 2857
    7. Miller et al. (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105: 3051-3057
    8. Gentilini et al. (2007) Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. Blood 110: 354
    9. Koehl et al. (2004) IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells Mol. Dis. 33: 261-266
    10. Passweg et al. (2006) Blood 108: 411
    11. Passweg, J. R. et al. (2004) Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 18: 1835-1838
    12. Rizzieri, D. A. et al. (2010) Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 16(8): 1107-1114
    13. Huenecke, S. et al. (2010)
      IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16
      and CD16
      subpopulations and
      in vivo
      influence after haploidentical NK cell infusion.
      J. Immunother. 33(2): 200-210
    14. Rubnitz. J. E. et al. (2010) NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J. Clin. Oncol. 28(6): 955-959
  • Selected references

  • Customer reports and application notes

  • Certificates of Analysis (CoA)

    Please follow this
    to search for certificates by lot number.
Product options: 3

CliniMACS CD3/CD56 Reagent Combination


CliniMACS CD3/CD56 Complete Kit


CliniMACS CD56 Reagent (271-01)

7.5 mL